Surgery for retroperitoneal and pelvic lymph node metastases of colorectal cancer

A. Ponomarenko, Yu. S. Khilkov, A. Arzamastseva, M. Panina, S. Achkasov, E. Rybakov
{"title":"Surgery for retroperitoneal and pelvic lymph node metastases of colorectal cancer","authors":"A. Ponomarenko, Yu. S. Khilkov, A. Arzamastseva, M. Panina, S. Achkasov, E. Rybakov","doi":"10.33878/2073-7556-2022-21-4-68-76","DOIUrl":null,"url":null,"abstract":"AIM: to evaluate the effect of surgery for metastases in retroperitoneal and pelvic lymph nodes on overall and disease-free survival.PATIENTS AND METHODS: the analysis included 30 patients with retroperitoneal lymph node metastases of colorectal cancer. Synchronous metastases to the retroperitoneal lymph nodes, were diagnosed in 21/30 (70%).RESULTS: the median overall and disease-free survival in patients who underwent lymphodissection was 32 and 13 months, respectively. Recurrence occurred in 14/30 (47%) patients. One-, two-, three-year disease-free survival was 61 ± 11%, 20 ± 11%, 0%; general 95 ± 4%, 74 ± 14%, 37 ± 19%, relatively. The median disease-free survival in the group with isolated retroperitoneal lymph node lesion was 14 (9–29) months and 10 (6–18) months in the group with retroperitoneal lymph node metastases in combination with synchronous liver lesion. One-and three-year disease-free survival was the same in the groups and was 58 ± 15% and 0%, p = 0.2. The univariate analysis did not reveal any factors related to overall and disease-free survival.CONCLUSION: in a selected group of patients with colorectal cancer, with lesions of retroperitoneal lymph nodes, including resectable metastases to the other organs, surgery can be justified, since it is accompanied by a relatively low rate of complications. However, the small cohort requires further study..","PeriodicalId":17840,"journal":{"name":"Koloproktologia","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2022-12-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Koloproktologia","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.33878/2073-7556-2022-21-4-68-76","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

AIM: to evaluate the effect of surgery for metastases in retroperitoneal and pelvic lymph nodes on overall and disease-free survival.PATIENTS AND METHODS: the analysis included 30 patients with retroperitoneal lymph node metastases of colorectal cancer. Synchronous metastases to the retroperitoneal lymph nodes, were diagnosed in 21/30 (70%).RESULTS: the median overall and disease-free survival in patients who underwent lymphodissection was 32 and 13 months, respectively. Recurrence occurred in 14/30 (47%) patients. One-, two-, three-year disease-free survival was 61 ± 11%, 20 ± 11%, 0%; general 95 ± 4%, 74 ± 14%, 37 ± 19%, relatively. The median disease-free survival in the group with isolated retroperitoneal lymph node lesion was 14 (9–29) months and 10 (6–18) months in the group with retroperitoneal lymph node metastases in combination with synchronous liver lesion. One-and three-year disease-free survival was the same in the groups and was 58 ± 15% and 0%, p = 0.2. The univariate analysis did not reveal any factors related to overall and disease-free survival.CONCLUSION: in a selected group of patients with colorectal cancer, with lesions of retroperitoneal lymph nodes, including resectable metastases to the other organs, surgery can be justified, since it is accompanied by a relatively low rate of complications. However, the small cohort requires further study..
结直肠癌腹膜后及盆腔淋巴结转移的手术治疗
目的:评价腹膜后和盆腔淋巴结转移手术对总生存率和无病生存率的影响。患者与方法:本研究纳入30例结直肠癌腹膜后淋巴结转移患者。同时转移到腹膜后淋巴结,诊断为21/30(70%)。结果:接受淋巴清扫的患者的中位总生存期和无病生存期分别为32个月和13个月。30例患者中有14例(47%)出现复发。1、2、3年无病生存率分别为61±11%、20±11%、0%;一般95±4%、74±14%、37±19%相对。孤立性腹膜后淋巴结病变组的中位无病生存期为14(9-29)个月,腹膜后淋巴结转移合并同步肝病变组的中位无病生存期为10(6-18)个月。两组1年和3年无病生存率相同,分别为58±15%和0%,p = 0.2。单变量分析未发现任何与总生存率和无病生存率相关的因素。结论:在选定的结直肠癌患者中,腹膜后淋巴结病变,包括可切除的转移到其他器官,手术是合理的,因为它伴随着相对低的并发症率。然而,这个小群体需要进一步的研究。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
1.00
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信